An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Hims & Hers, the consumer health company known for selling things like hair loss and sexual health treatments online, says it plans to quickly expand into selling peptide therapies — including substances like BPC-157. The company made the announcement as part of its business update, framing peptides as a new product category it expects to scale up fast. The snippet doesn’t give a detailed timeline or say if they already have those products for sale to everyone. BPC-157 is one of the peptides mentioned. A peptide is basically a very short protein — think of it as a tiny fragment of something your body already uses. People who talk about BPC-157 say it can help with repair and recovery in tissues like tendons, gut lining, and muscles. But it’s not a mainstream, approved medicine the way aspirin or insulin are. Much of the interest comes from lab studies and anecdotes, not large, conclusive human trials. The announcement is mainly a business plan, not new medical evidence. It tells investors that Hims & Hers intends to enter a growing market where demand is driven by people seeking recovery, wellness, or anti-aging treatments. The snippet doesn’t report a new clinical trial showing BPC-157 works in people. So the “research” part here is really market opportunity and company strategy rather than proof that these peptides are effective or safe in the long term for most people. This matters because a familiar consumer brand moving into peptides could make them easier to buy and more visible to everyday people. For someone curious about recovery from injuries, chronic gut issues, or cosmetic improvements, that could feel promising. It also means more clinics and direct-to-consumer shops might start offering these therapies, which could lower barriers to access — both good and bad depending on the evidence and oversight that accompanies them. There are important caveats and risks. Many peptides like BPC-157 are not approved drugs with clear dosing, safety profiles, or proven benefits for most uses. Side effects, long-term risks, and interactions with other medicines are often not well studied. Regulatory status varies: some peptides are sold as research chemicals or supplements in gray areas rather than as regulated prescriptions. People who are pregnant, breastfeeding, have serious health conditions, or take other medications should be especially cautious. Always check with a qualified clinician and look for reliable evidence before trying a new therapy. Bottom line: Hims & Hers wants to sell peptide therapies more widely, but that’s a business move, not proof those therapies are safe or effective for everyday use.
Source: glossy.co